Best Industrial Disributor Stocks To Watch Right Now

Best Industrial Disributor Stocks To Watch Right Now: Acura Pharmaceuticals Inc.(ACUR)

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, and decongestants. The company offers OXECTA Tablets CII, which are oral formulations of oxycodone HCl for the management of acute and chronic moderate to severe pain; and Impede PSE, a pseudoephedrine hydrochloride tablet product candidate. It is also developing opioid analgesic product candidates, which would be used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. In addition, the company investigates and develops mechanisms to incorporate abuse deterrent features into abused and misused pharmaceutical products using its Impede Technology. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize certain opioid analgesic products utilizing the company?s proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.

Advisors' Opinion:

• [By Rick Munarriz]

  Thursday
  Acura Pharmaceuticas (NASDAQ: ACUR  ) checks in on Thursday. Drugmakers use Acura's Aversion and Impede technologies to create ab! use-deterrent treatments. In short, if an abuser tries to extract the active ingredient of a drug to heighten addictive experiences, Acura's technologies kick in to make the whole dose unusable.

• [By Sean Williams]

  ALKS-7106 for the treatment of pain has big potential as it encompasses a broad audience, but it'll need to overcome the common stigma of pain drugs with regard to easy abuse potential. According to the press release, Alkermes will be introducing newer technology that will make its opioid-based drug more resistant to abuse. It should be curious to see how well this performs as there aren't many successful abuse-resistant drugs, or companies developing those drugs for that matter. Acura Pharmaceuticals (NASDAQ: ACUR  ) , for instance, successfully brought moderate-to-severe painkiller Oxecta to market in 2011 (which it subsequently licensed to Pfizer) and a bioequivalent version of decongestant pseudoephedrine to market last year, but sales of neither drug has exactly taken off. Like with its MMF prodrug, Alkermes anticipates a mid-2014 clinical trial launch date.

• [By John Udovich]

  On Tuesday, small cap specialty pharmaceutical company Acura Pharmaceuticals, Inc (NASDAQ: ACUR) surged 27.52% to $1.90 on no apparent news beyond a speculative Seeking Alpha article that talked about certain catalysts  – meaning its worth taking a closer look at the company to see what's going on and whether shares could move higher. 

source from Top Stocks For 2015:http://www.topstocksblog.com/best-industrial-disributor-stocks-to-watch-right-now.html